Abbott Labs's most recent trend suggests a bullish bias. One trading opportunity on Abbott Labs is a Bull Put Spread using a strike $44.00 short put and a strike $39.00 long put offers a potential 5.04% return on risk over the next 25 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $44.00 by expiration. The full premium credit of $0.24 would be kept by the premium seller. The risk of $4.76 would be incurred if the stock dropped below the $39.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Abbott Labs is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Abbott Labs is bullish.
The RSI indicator is at 50.29 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Abbott Labs
ABBOTT LABORATORIES Files SEC form 8-K, Change in Directors or Principal Officers
Tue, 23 Dec 2014 22:04:04 GMT
Rising Services Spending Could Prop Up Healthcare, Tech ETFs
Tue, 23 Dec 2014 20:33:41 GMT
ETF Trends – Consumer services spending remains relatively weak. However, if services spending picks up, healthcare and technology exchange traded funds could capitalize on the growth. Chad Morganlander, portfolio …
Chilean quits company boards to fight U.S. insider trading charges
Tue, 23 Dec 2014 19:29:47 GMT
Reuters – A Chilean businessman charged by U.S. regulators with insider trading linked to Abbott Laboratories $2.9 billion acquisition of a pharmaceutical firm said on Tuesday he had quit several board positions …
Abbott Completes Acquisition of Topera, Inc.
Mon, 22 Dec 2014 21:30:00 GMT
PR Newswire – ABBOTT PARK, Ill., Dec. 22, 2014 /PRNewswire/ — Abbott (ABT) today announced that it has completed its acquisition of Topera, Inc., a private, venture-backed medical device company focused on developing innovative electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation, one of the most common heart rhythm disorders in the world. Catheter-based electrophysiology is an approximately $3 billion global market that has been growing annually at double-digit rates. Topera has developed a novel diagnostic catheter and mapping software, or rotor identification system, which helps physicians identify and target patient-specific rotors that have been shown to be the sustaining mechanism for atrial fibrillation. The ability to locate these rotors enables the physician to individualize patient treatment through a procedure referred to as Focal Impulse and Rotor Mapping guided ablation, or FIRM-guided ablation.
Abbott to Present at J.P. Morgan Healthcare Conference
Thu, 18 Dec 2014 14:00:00 GMT
PR Newswire – ABBOTT PARK, Ill., Dec. 18, 2014 /PRNewswire/ — Abbott (NYSE: ABT) will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2015. Thomas C. Freyman, executive vice president, …
Also on Market Tamer…
Follow Us on Facebook